Is Using Sodium-Glucose Cotransporter-2 Inhibitors to Treat Adults with Chronic Heart Failure Cost-Effective? A Systematic Review of Cost-Effectiveness Studies
ConclusionsUsing SGLT2i to treat heart failure is cost-effective, with more certainty in LVEF ≤ 40% compared to LVEF> 40%. Policymakers in jurisdictions where economic evaluations are not available could potentially use this study ’s findings to make informed decisions about treatment adoption.Systematic Review Protocol RegistrationThis study protocol was registered with the International Prospective Register of Systematic Reviews (PROSPERO; CRD42023388701).
Source: Applied Health Economics and Health Policy - Category: Health Management Source Type: research
More News: Cardiology | Dapagliflozin | Databases & Libraries | Economics | Empagliflozin | Forxiga | Health Management | Heart | Heart Failure | Jardiance | Sodium | Study | UK Health